SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for BCYC.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 71.10M
March 31, 2026 75.75M
December 31, 2025 79.52M
September 30, 2025 80.05M
June 30, 2025 79.75M
March 31, 2025 77.01M
December 31, 2024 72.18M
September 30, 2024 65.78M
June 30, 2024 63.52M
March 31, 2024 62.39M
December 31, 2023 60.64M
September 30, 2023 56.40M
June 30, 2023 50.17M
March 31, 2023 47.06M
December 31, 2022 49.30M
September 30, 2022 47.39M
June 30, 2022 45.51M
March 31, 2022 41.12M
Date Value
December 31, 2021 32.42M
September 30, 2021 34.51M
June 30, 2021 33.72M
March 31, 2021 32.60M
December 31, 2020 29.44M
September 30, 2020 21.94M
June 30, 2020 19.41M
March 31, 2020 16.16M
December 31, 2019 14.60M
September 30, 2019 13.37M
June 30, 2019 10.94M
March 31, 2019 9.664M
December 31, 2018 8.227M
September 30, 2018 8.554M
June 30, 2018 6.226M
March 31, 2018 4.545M
December 31, 2017 2.543M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Autolus Therapeutics Plc 152.92M
Biodexa Pharmaceuticals Plc 6.375M
Akari Therapeutics Plc 8.796M
DBV Technologies SA 56.62M
Cellectis SA 21.32M